Cargando…

PET Stress Testing with Coronary Flow Capacity in the Evaluation of Patients with Coronary Artery Disease and Left Ventricular Dysfunction: Rethinking the Current Paradigm

PURPOSE OF REVIEW: Cardiomyopathy with underlying left ventricular (LV) dysfunction is a heterogenous group of disorders that may be present with, and/or secondary to, coronary artery disease (CAD). The purpose of this review is to demonstrate, via case illustrations, the benefits offered by cardiac...

Descripción completa

Detalles Bibliográficos
Autores principales: Bober, Robert M., Milani, Richard V., Krim, Selim R., Morin, Daniel P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990801/
https://www.ncbi.nlm.nih.gov/pubmed/33761005
http://dx.doi.org/10.1007/s11886-021-01478-3
_version_ 1783669125235605504
author Bober, Robert M.
Milani, Richard V.
Krim, Selim R.
Morin, Daniel P.
author_facet Bober, Robert M.
Milani, Richard V.
Krim, Selim R.
Morin, Daniel P.
author_sort Bober, Robert M.
collection PubMed
description PURPOSE OF REVIEW: Cardiomyopathy with underlying left ventricular (LV) dysfunction is a heterogenous group of disorders that may be present with, and/or secondary to, coronary artery disease (CAD). The purpose of this review is to demonstrate, via case illustrations, the benefits offered by cardiac positron-emission tomography (PET) stress testing with coronary flow capacity (CFC) in the evaluation and treatment of patients with left ventricular (LV) dysfunction and CAD. RECENT FINDINGS: CFC, a metric that is increasing in prominence, represents the integration of several absolute perfusion metrics into clinical strata of CAD severity. Our prior work has demonstrated improvement in regional perfusion metrics as a result of revascularization to territories with severe reduction in CFC. Conversely, when CFC is adequate, there is no change in regional perfusion metrics following revascularization, despite angiographically severe stenosis. Furthermore, Gould et al. demonstrated decreased rates of myocardial infarction and death following revascularization of myocardium with severely reduced CFC, with no clinical benefit observed following revascularization of patients with preserved CFC. In a series of cases, we present pre-revascularization and post-revascularization PET scans with perfusion metrics in patients with LV dysfunction and CAD. In these examples, we demonstrate improvement in LV function and perfusion metrics following revascularization only in cases where baseline CFC is severely reduced. SUMMARY: PET with CFC offers unique guidance regarding revascularization in patients with reduced LV function and CAD.
format Online
Article
Text
id pubmed-7990801
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-79908012021-04-12 PET Stress Testing with Coronary Flow Capacity in the Evaluation of Patients with Coronary Artery Disease and Left Ventricular Dysfunction: Rethinking the Current Paradigm Bober, Robert M. Milani, Richard V. Krim, Selim R. Morin, Daniel P. Curr Cardiol Rep Nuclear Cardiology (V Dilsizian, Section Editor) PURPOSE OF REVIEW: Cardiomyopathy with underlying left ventricular (LV) dysfunction is a heterogenous group of disorders that may be present with, and/or secondary to, coronary artery disease (CAD). The purpose of this review is to demonstrate, via case illustrations, the benefits offered by cardiac positron-emission tomography (PET) stress testing with coronary flow capacity (CFC) in the evaluation and treatment of patients with left ventricular (LV) dysfunction and CAD. RECENT FINDINGS: CFC, a metric that is increasing in prominence, represents the integration of several absolute perfusion metrics into clinical strata of CAD severity. Our prior work has demonstrated improvement in regional perfusion metrics as a result of revascularization to territories with severe reduction in CFC. Conversely, when CFC is adequate, there is no change in regional perfusion metrics following revascularization, despite angiographically severe stenosis. Furthermore, Gould et al. demonstrated decreased rates of myocardial infarction and death following revascularization of myocardium with severely reduced CFC, with no clinical benefit observed following revascularization of patients with preserved CFC. In a series of cases, we present pre-revascularization and post-revascularization PET scans with perfusion metrics in patients with LV dysfunction and CAD. In these examples, we demonstrate improvement in LV function and perfusion metrics following revascularization only in cases where baseline CFC is severely reduced. SUMMARY: PET with CFC offers unique guidance regarding revascularization in patients with reduced LV function and CAD. Springer US 2021-03-24 2021 /pmc/articles/PMC7990801/ /pubmed/33761005 http://dx.doi.org/10.1007/s11886-021-01478-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Nuclear Cardiology (V Dilsizian, Section Editor)
Bober, Robert M.
Milani, Richard V.
Krim, Selim R.
Morin, Daniel P.
PET Stress Testing with Coronary Flow Capacity in the Evaluation of Patients with Coronary Artery Disease and Left Ventricular Dysfunction: Rethinking the Current Paradigm
title PET Stress Testing with Coronary Flow Capacity in the Evaluation of Patients with Coronary Artery Disease and Left Ventricular Dysfunction: Rethinking the Current Paradigm
title_full PET Stress Testing with Coronary Flow Capacity in the Evaluation of Patients with Coronary Artery Disease and Left Ventricular Dysfunction: Rethinking the Current Paradigm
title_fullStr PET Stress Testing with Coronary Flow Capacity in the Evaluation of Patients with Coronary Artery Disease and Left Ventricular Dysfunction: Rethinking the Current Paradigm
title_full_unstemmed PET Stress Testing with Coronary Flow Capacity in the Evaluation of Patients with Coronary Artery Disease and Left Ventricular Dysfunction: Rethinking the Current Paradigm
title_short PET Stress Testing with Coronary Flow Capacity in the Evaluation of Patients with Coronary Artery Disease and Left Ventricular Dysfunction: Rethinking the Current Paradigm
title_sort pet stress testing with coronary flow capacity in the evaluation of patients with coronary artery disease and left ventricular dysfunction: rethinking the current paradigm
topic Nuclear Cardiology (V Dilsizian, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990801/
https://www.ncbi.nlm.nih.gov/pubmed/33761005
http://dx.doi.org/10.1007/s11886-021-01478-3
work_keys_str_mv AT boberrobertm petstresstestingwithcoronaryflowcapacityintheevaluationofpatientswithcoronaryarterydiseaseandleftventriculardysfunctionrethinkingthecurrentparadigm
AT milanirichardv petstresstestingwithcoronaryflowcapacityintheevaluationofpatientswithcoronaryarterydiseaseandleftventriculardysfunctionrethinkingthecurrentparadigm
AT krimselimr petstresstestingwithcoronaryflowcapacityintheevaluationofpatientswithcoronaryarterydiseaseandleftventriculardysfunctionrethinkingthecurrentparadigm
AT morindanielp petstresstestingwithcoronaryflowcapacityintheevaluationofpatientswithcoronaryarterydiseaseandleftventriculardysfunctionrethinkingthecurrentparadigm